SOST and sclerosteosis: Several lines of evidence to support this hypothesis include (i) patients with sclerosteosis due to deficiency of sclerostin have higher areal BMD at the radius as well as the lumbar spine and hip (17) and (ii) appropriate doses of anti-sclerostin antibodies effectively increase bone mass in animals with skeletal disuse or unloading (18, 19).